Related Experiment Videos
Circulating immune complexes in childhood malignancies: a Pediatric Oncology Group study
Summary
Circulating immune complexes (CIC) showed minimal value in assessing pediatric cancer activity or treatment response. Elevated CIC levels in children did not correlate with disease features, unlike in adults where it impacts survival.
Area of Science:
- Pediatric Oncology
- Immunology
- Biomarkers
Background:
- Circulating immune complexes (CIC) are implicated in various diseases.
- Their role in pediatric malignancies requires further elucidation.
Purpose of the Study:
- To investigate the prevalence and clinical significance of CIC in children with various cancers.
- To determine if CIC levels correlate with disease activity, treatment response, or prognosis in pediatric patients.
Main Methods:
- Serum samples from 89 children diagnosed with acute lymphocytic leukemia (ALL), acute non-lymphocytic leukemia (AML), neuroblastoma (NB), or osteosarcoma (OS) were analyzed.
- The [125I]Clq binding assay was used to quantify CIC levels.
- Immunoglobulin levels were also measured.
Main Results:
- Increased CIC levels were detected at diagnosis in 9% of ALL, 22% of AML, 42% of NB, and 50% of OS patients.
- Higher CIC prevalence was noted in stage IV neuroblastoma.
- No significant correlation was found between initial CIC levels and clinical features, treatment response, prognosis, or infection.
- Longitudinal sampling did not establish a clear link between disease activity and CIC quantity.
Conclusions:
- Quantitating CIC has minimal value for assessing disease activity or predicting treatment response in pediatric malignancies.
- Findings contrast with adult studies where elevated CIC correlates with poorer outcomes.